|

Aromatase Inhibitor Clinical Trials

4 actively recruiting trials across 2 locations

Also known as: AI, Anastrozole (Arimidex), Exemestane (Aromasin), Letrozole (Femara)

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 1

Top Sponsors

  • Hebei Medical University Fourth Hospital1
  • Finn, Olivera, PhD1
  • BeOne Medicines1
  • Astellas Pharma Global Development, Inc.1

Indications

  • Breast Cancer4
  • Cancer4
  • Hot Flashes1
  • Ductal Carcinoma in Situ1
  • Advanced Solid Tumor1

Other2 trials

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Phase 3
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Phase 2

St Louis, Missouri1 trial

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Washington University in St Louis

Phase 1

Pittsburgh, Pennsylvania1 trial

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

UPMC Magee Womens Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.